Mesoblast is a biopharmaceutical company that is focused on developing and commercializing allogeneic cellular medicines for a range of diseases including cardiovascular, spine orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. It has a proprietary regenerative medicine technology platform based on mesenchymal lineage cells. The company is currently involved in several Phase III clinical trials for the treatment of acute graft versus host disease, chronic heart failure, chronic low back pain, rheumatoid arthritis diabetic nephropathy and wound healing.